Uptake mechanism and endosomal fate of drug-phospholipid lipid nanoparticles in subcutaneous and in situ hepatoma.

摘要: Drug-phospholipid lipid nanoparticles (DPLNs) can effectively enhance the properties of traditional solid (SLNs) and nanostructured carriers (NLCs), as previously demonstrated by our research group others. To date, however, very few studies have focused on cellular uptake mechanism fate DPLNs in hepatoma. Therefore, we systematically studied endosomal through vitro vivo experiments. Confocal laser scanning microscopy (CLSM) flow cytometry that Raw264.7 cell line (macrophage cells), Chang cells (a human liver line) HepG2 hepatoma exhibited distinct mechanisms. The served a model for examining liver-targeting ability. results from mice with subcutaneous hepatomas situ confirmed tumor-targeting property was associated drug reservoir function. These findings further improve understanding clinical applications.